ACE2 and infection: Different ACE2-Fc decoys have been designed and shown to prevent infections by the parental SARS-CoV-2 strain and a broad range of variants like Omicron in animal and human tissue models, and different recombinant ACE2 variants are currently in clinical trials (Lei et al., 2020; Higuchi et al., 2021; Huang et al., 2021; Ikemura et al., 2022; Zhang et al., 2023).